Most patients were enrolled at a single tertiary academic cancer center (DFCI) where providers already had familiarity with adjuvant de-escalation trials in HER2+ breast cancer based on participation in prior protocols, which may have impacted their comfort level with this approach and experience presenting it to prospective participants. The gene discussed is ERBB2; the disease is breast cancer.